Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

Cancer Treatment Reviews

Volumn 41, Issue 6, 2015, Pages 547-553

  Anestis, Aristomenis ^a   Karamouzis, Michalis V ^a   Dalagiorgou, Georgia ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Androgen receptor; Breast cancer; Estrogen receptor; Triple negative

Indexed keywords

ABIRATERONE ACETATE; AEZS 125; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BICALUTAMIDE; ENZALUTAMIDE; PREDNISONE; UNCLASSIFIED DRUG; ZOPTARELIN DOXORUBICIN; ANTIANDROGEN; AR PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL MOTILITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; FEMALE; PHYSIOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANDROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84937643430     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.04.009     Document Type: Review

References (67)

1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014, 64:52-62.
2. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
3. Santagata S., Thakkar A., Ergonul A., Wang B., Woo T., Hu R., et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 2014, 124:859-870.
4. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
5. de Ruijter T.C., Veeck J., de Hoon J.P., van Engeland M., Tjan-Heijnen V.C. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011, 137:183-192.
6. Bosch A., Eroles P., Zaragoza R., Vina J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36:206-215.
7. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
8. Metzger-Filho O., Tutt A., de Azambuja E., Saini K.S., Viale G., Loi S., et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012, 30:1879-1887.
9. Jiao Q., Wu A., Shao G., Peng H., Wang M., Ji S., et al. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014, 6:1329-1335.
10. McNamara K.M., Yoda T., Takagi K., Miki Y., Suzuki T., Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013, 133:66-76.
11. McNamara K.M., Moore N.L., Hickey T.E., Sasano H., Tilley W.D. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014, 21:T161-T181.
12. Safarpour D., Pakneshan S., Tavassoli F.A. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res 2014, 4:353-368.
13. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012, 23(Suppl 6):vi56-vi65.
14. Viale G. The current state of breast cancer classification. Ann Oncol 2012, 23(Suppl 10):x207-x210.
15. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
16. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas N.
17. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
18. Xu H., Eirew P., Mullaly S.C., Aparicio S. The omics of triple-negative breast cancers. Clin Chem 2014, 60:122-133.
19. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2010, 15(Suppl 5):39-48.
20. Park H.S., Jang M.H., Kim E.J., Kim H.J., Lee H.J., Kim Y.J., et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol 2014, 27:1212-1222.
21. Baselga J., Gomez P., Greil R., Braga S., Climent M.A., Wardley A.M., et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013, 31:2586-2592.
22. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
23. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K.K., Carter S.L., Frederick A.M., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
24. Barbie T.U., Alexe G., Aref A.R., Li S., Zhu Z., Zhang X., et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014, 124:5411-5423.
25. Gucalp A., Tolaney S., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A., et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013, 19:5505-5512.
26. Paul A., Gunewardena S., Stecklein S.R., Saha B., Parelkar N., Danley M., et al. PKClambda/iota signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ 2014, 21:1469-1481.
27. Karamouzis M.V., Gorgoulis V.G., Papavassiliou A.G. Transcription factors and neoplasia: vistas in novel drug design. Clin Cancer Res 2002, 8:949-961.
28. Tsang J.Y., Ni Y.B., Chan S.K., Shao M.M., Law B.K., Tan P.H., et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol 2014, 21:2218-2228.
29. Lim E., Ni M., Cao S., Hazra A., Tamimi R.M., Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014, 6:71-78.
30. Hickey T.E., Robinson J.L., Carroll J.S., Tilley W.D. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol 2012, 26:1252-1267.
31. Gonzalez-Angulo A.M., Stemke-Hale K., Palla S.L., Carey M., Agarwal R., Meric-Berstam F., et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009, 15:2472-2478.
32. McGhan L.J., McCullough A.E., Protheroe C.A., Dueck A.C., Lee J.J., Nunez-Nateras R., et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2014, 21:361-367.
33. McNamara K.M., Yoda T., Nurani A.M., Shibahara Y., Miki Y., Wang L., et al. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat 2014, 145:281-293.
34. Pistelli M., Caramanti M., Biscotti T., Santinelli A., Pagliacci A., De Lisa M., et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers 2014, 6:1351-1362.
35. Thike A.A., Yong-Zheng Chong L., Cheok P.Y., Li H.H., Wai-Cheong Yip G., Huat Bay B., et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014, 27:352-360.
36. Witzel I., Graeser M., Karn T., Schmidt M., Wirtz R., Schutze D., et al. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J Cancer Res Clin Oncol 2013, 139:809-816.
37. McNamara K.M., Yoda T., Miki Y., Chanplakorn N., Wongwaisayawan S., Incharoen P., et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci 2013, 104:639-646.
38. Choi J.E., Kang S.H., Lee S.J., Bae Y.K. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015, 22:82-89.
39. Vera-Badillo F.E., Templeton A.J., de Gouveia P., Diaz-Padilla I., Bedard P.L., Al-Mubarak M., et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014, 106:djt319.
40. Qu Q., Mao Y., Fei X.C., Shen K.W. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One 2013, 8:e82650.
41. Park J.J., Irvine R.A., Buchanan G., Koh S.S., Park J.M., Tilley W.D., et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000, 60:5946-5949.
42. Spurdle A.B., Antoniou A.C., Duffy D.L., Pandeya N., Kelemen L., Chen X., et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005, 7:R176-R183.
43. Lanzino M., Garofalo C., Morelli C., Le Pera M., Casaburi I., McPhaul M.J., et al. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res Treat 2009, 115:297-306.
44. Lin D.Y., Fang H.I., Ma A.H., Huang Y.S., Pu Y.S., Jenster G., et al. Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 2004, 24:10529-10541.
45. King T.D., Suto M.J., Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012, 113:13-18.
46. Yang F., Li X., Sharma M., Sasaki C.Y., Longo D.L., Lim B., et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002, 277:11336-11344.
47. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
48. Robinson J.L., Macarthur S., Ross-Innes C.S., Tilley W.D., Neal D.E., Mills I.G., et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 2011, 30:3019-3027.
49. Lehmann-Che J., Hamy A.S., Porcher R., Barritault M., Bouhidel F., Habuellelah H., et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 2013, 15:R37.
50. Moore N.L., Buchanan G., Harris J.M., Selth L.A., Bianco-Miotto T., Hanson A.R., et al. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer 2012, 19:599-613.
51. Cuenca-Lopez M.D., Montero J.C., Morales J.C., Prat A., Pandiella A., Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014, 14:302.
52. Garay J.P., Karakas B., Abukhdeir A.M., Cosgrove D.P., Gustin J.P., Higgins M.J., et al. The growth response to androgen receptor signaling in ERalpha-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 2012, 14:R27.
53. Tarulli G.A., Butler L.M., Tilley W.D., Hickey T.E. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer 2014, 21:T183-T202.
54. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002, 277:7076-7085.
55. Bartholomeusz C., Gonzalez-Angulo A.M., Liu P., Hayashi N., Lluch A., Ferrer-Lozano J., et al. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 2012, 17:766-774.
56. Lehmann B.D., Bauer J.A., Schafer J.M., Pendleton C.S., Tang L., Johnson K.C., et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014, 16:406.
57. Dimitrakakis C., Bondy C. Androgens and the breast. Breast Cancer Res 2009, 11:212.
58. Fost C., Duwe F., Hellriegel M., Schweyer S., Emons G., Grundker C. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 2011, 25:1481-1487.
59. Seitz S., Buchholz S., Schally A.V., Weber F., Klinkhammer-Schalke M., Inwald E.C., et al. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer 2014, 14:847.
60. Cochrane D.R., Bernales S., Jacobsen B.M., Cittelly D.M., Howe E.N., D'Amato N.C., et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014, 16:R7.
61. Stage 1 results from MDV3100-11: a 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor. In: Advanced AR+ triple-negative breast cancer (TNBC) 37th annual San Antonio breast cancer symposium, 2014.
62. Kwok C.W., Treeck O., Buchholz S., Seitz S., Ortmann O., Engel J.B. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol 2014.
63. Rizza P., Barone I., Zito D., Giordano F., Lanzino M., De Amicis F., et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 2014, 16:R21.
64. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26:3727-3734.
65. Shanle E.K., Zhao Z., Hawse J., Wisinski K., Keles S., Yuan M., et al. Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. Mol Endocrinol 2013, 27:1762-1775.
66. Roman-Blas J.A., Castaneda S., Cutolo M., Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor beta agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res 2010, 62:1588-1593.
67. Lindberg K., Helguero L.A., Omoto Y., Gustafsson J.A., Haldosen L.A. Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 2011, 13:R43.